CEBPA and acute myeloid leukemia: For example, Marcucci G et al. reported the increased expression of all members of miR-181 family in patients with favorable risk (cytogenetically normal AML (CN-AML) with CEBPA mutations) [40] and its decreased expression in a high risk subgroup (CN-AML with FLT3-ITD and/or wild-type NPM1) [45].